News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lightlake Therapeutics Inc. to Discuss with King's College London’s Institute of Psychiatry on the Development of a New Opiate Overdose Treatment


1/4/2012 6:35:54 AM

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it is seeking to collaborate with Europe's largest centre for research and post-graduate education in psychiatry, King’s College London Institute of Psychiatry, to develop a new treatment for opiate overdose.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES